Sumitomo Mitsui Trust Group Inc. decreased its stake in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 5.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 6,233,693 shares of the company's stock after selling 384,701 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 1.64% of Standard BioTools worth $6,732,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in LAB. Takeda Pharmaceutical Co. Ltd. purchased a new stake in Standard BioTools during the 4th quarter worth about $29,000. Two Sigma Securities LLC bought a new position in shares of Standard BioTools during the 4th quarter valued at about $30,000. Aquatic Capital Management LLC bought a new position in Standard BioTools during the 4th quarter worth approximately $45,000. Cibc World Markets Corp bought a new position in Standard BioTools during the 4th quarter worth approximately $48,000. Finally, KLP Kapitalforvaltning AS bought a new position in Standard BioTools during the 4th quarter worth approximately $70,000. Hedge funds and other institutional investors own 53.74% of the company's stock.
Standard BioTools Trading Down 1.8%
Shares of LAB stock traded down $0.03 during trading hours on Friday, reaching $1.35. The company's stock had a trading volume of 860,377 shares, compared to its average volume of 1,952,295. The stock has a market capitalization of $510.86 million, a P/E ratio of -3.84 and a beta of 1.54. Standard BioTools Inc. has a one year low of $0.92 and a one year high of $2.41. The firm's fifty day simple moving average is $1.11 and its 200 day simple moving average is $1.30.
Standard BioTools Profile
(
Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Further Reading
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
